Annals of Clinical and Translational Neurology

Article	Citations
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”	467
Blood neurofilament light: a critical review of its application to neurologic disease	155
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France	95
Long COVID‐19: Objectifying most self‐reported neurological symptoms	88
Anakinra usage in febrile infection related epilepsy syndrome: an international cohort	87
Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study	69
Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19	65
Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study	61
Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy	57
Diaphragm dysfunction in severe COVID‐19 as determined by neuromuscular ultrasound	57
Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis	55
A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy	52
230 days of ultra long‐term subcutaneous EEG: seizure cycle analysis and comparison to patient diary	50
QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions	48
Evolution of neurologic symptoms in non‐hospitalized COVID‐19 “long haulers”	47
Experiences of telemedicine in neurological out‐patient clinics during the COVID‐19 pandemic	47
Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study	44
The brain–heart interaction in epilepsy: implications for diagnosis, therapy, and SUDEP prevention	43
Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients	43
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy	42
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes	41
Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface	40
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder	39
Acute disseminated encephalomyelitis in a patient vaccinated against SARS‐CoV‐2	39
Spinocerebellar ataxia clinical trials: opportunities and challenges	38

Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children	37
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment	37
Obesity and the risk of Multiple Sclerosis. The role of Leptin	37
Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome	36
Synaptic density in carriers of C9orf72 mutations: a [11C]UCB‐J PET study	35
Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy	35
Interictal spike networks predict surgical outcome in patients with drug‐resistant focal epilepsy	35
Mendelian etiologies identified with whole exome sequencing in cerebral palsy	33
Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes	32
Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease	31
Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses	31
Multiple sclerosis, rituximab, and COVID‐19	31
Artificial intelligence extension of the OSCAR‐IB criteria	31
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy	31
Clinical efficacy of plasma exchange in patients with autoimmune encephalitis	30
Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia	30
Longitudinal evaluation of neurologic‐post acute sequelae SARS‐CoV‐2 infection symptoms	30
Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy	29
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population	29
Ring trial of 2nd generation RT‐QuIC diagnostic tests for sporadic CJD	28
Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis	28
Gut microbiome is associated with multiple sclerosis activity in children	28
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy	28
Prevalence and patterns of symptoms of dysautonomia in patients with long‐COVID syndrome: A cross‐sectional study	28
KCNQ2‐DEE: developmental or epileptic encephalopathy?	27
Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy	26
Delta power robustly predicts cognitive function in Angelman syndrome	26
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease	26
Mortality of neuromyelitis optica spectrum disorders in a Chinese population	26
Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder	25
Lipid levels and the risk of dementia: A dose–response meta‐analysis of prospective cohort studies	25
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS	25
A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica	25
Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study	25
Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia	24
Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study	24
CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis	24
Mechanistic underpinning of an inside–out concept for autoimmunity in multiple sclerosis	24
The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease	24
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease	24
Subcortical short‐term plasticity elicited by deep brain stimulation	23
Development of an age‐adjusted model for blood neurofilament light chain	23
Trait impulsivity in Juvenile Myoclonic Epilepsy	23
Brain volumetric deficits in MAPT mutation carriers: a multisite study	23
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy	23
Resection of piriform cortex predicts seizure freedom in temporal lobe epilepsy	23
Comparison of plasma and CSF biomarkers in predicting cognitive decline	22
Central nervous system vascular malformations: A clinical review	22
GGC repeat expansions in NOTCH2NLC causing a phenotype of distal motor neuropathy and myopathy	22
Motor beta cortical oscillations are related with the gait kinematics of youth with cerebral palsy	22

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis	22
Acute epileptiform abnormalities are the primary predictors of post‐stroke epilepsy: a matched, case–control study	22
Baseline characteristics of the North American prodromal Synucleinopathy cohort	22
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)	22
Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome	21
SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder	20
TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis	20
Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study	20
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases	20
Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis	20
Younger age of stroke in low‐middle income countries is related to healthcare access and quality	20
Prognostic value of serum/plasma neurofilament light chain for COVID‐19‐associated mortality	20
Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers	20
Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers	20
Predictors of cognitive decline in older individuals without dementia: An updated meta‐analysis	19
Leveraging electronic health records data to predict multiple sclerosis disease activity	19
Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months	19
Associations ofsNfLwith clinico‐radiological measures in a largeMSpopulation	19
Genetic prediction of impulse control disorders in Parkinson's disease	19
Clinical utility of anti‐cytosolic 5’‐nucleotidase 1A antibody in idiopathic inflammatory myopathies	19
Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS‐FTD spectrum	18
Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts	18
Sustained immunotolerance in multiple sclerosis after stem cell transplant	18
A meta‐analysis of the global impact of the COVID‐19 pandemic on stroke care & the Houston Experience	18
Lack of progression of beta dynamics after long‐term subthalamic neurostimulation	18
Early‐onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late‐onset	18
Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages	18
Physical activity level and stroke risk in US population: A matched case–control study of 102,578 individuals	18
Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes	18
Structural brain changes in post‐acute COVID‐19 patients with persistent olfactory dysfunction	17
Assessing the role of rare genetic variants in drug‐resistant, non‐lesional focal epilepsy	17
Initial findings in traumatic peripheral nerve injury and repair with diffusion tensor imaging	17
Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies	17
Sirolimus for epileptic seizures associated with focal cortical dysplasia type II	17
Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia	17
Expanding the phenotypic spectrum of BCS1L‐related mitochondrial disease	17
Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study	17
Diagnostic capabilities of nanopore long‐read sequencing in muscular dystrophy	17
Functional dystonia: A case‐control study and risk prediction algorithm	16
CD8+ T cell subpopulations and pro‐inflammatory cytokines in neuromyelitis optica spectrum disorder	16
Wearable myoelectric interface enables high‐dose, home‐based training in severely impaired chronic stroke survivors	16
No strong HLA association with MOG antibody disease in the UK population	16
Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle	16
In‐depth peripheral CD4+ T profile correlates with myasthenic crisis	16
Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis	16
Evaluation of SORD mutations as a novel cause of Charcot‐Marie‐Tooth disease	16
Impact of T cells on neurodegeneration in anti‐GAD65 limbic encephalitis	15
The kynurenine pathway relates to post‐acuteCOVID‐19 objective cognitive impairment andPASC	15
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review	15
Factors influencing the acute pentylenetetrazole‐induced seizure paradigm and a literature review	15
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease	15
Plasma lipidomics of monozygotic twins discordant for multiple sclerosis	15
JKAP relates to disease risk, severity, and Th1 and Th17 differentiation in Parkinson's disease	14
Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features	14
Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States	14
TRPV4 mutations causing mixed neuropathy and skeletal phenotypes result in severe gain of function	14
Scientific rationale for a higher dose of nusinersen	14
Spinocerebellar ataxia type 14: refining clinicogenetic diagnosis in a rare adult‐onset disorder	14
Home‐based biofeedback speech treatment improves dysarthria in repeat‐expansion SCAs	14
Genetic spectrum in a cohort of patients with distal hereditary motor neuropathy	14
PI4K2A deficiency causes innate error in intracellular trafficking with developmental and epileptic‐dyskinetic encephalopathy	14
Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria	14
Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization	14
Congenital myasthenic syndrome in China: genetic and myopathological characterization	14
Nusinersen in type 0 spinal muscular atrophy: should we treat?	13
A population‐based meta‐analysis of circulating GFAP for cognition and dementia risk	13
Disease progression in Parkinson‘s disease patients with subjective cognitive complaint	13
Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease	13
Systematic review of CMTX1 patients with episodic neurological dysfunction	13
Nanopore 16S sequencing enhances the detection of bacterial meningitis after neurosurgery	13
Altered executive control network connectivity in anti‐NMDA receptor encephalitis	13
Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease	13
Novel SPTBN2 gene mutation and first intragenic deletion in early onset spinocerebellar ataxia type 5	13
Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay	13
Recognizing early MRI signs (or their absence) is crucial in diagnosing metachromatic leukodystrophy	13
Ante‐ and postmortem tau in autosomal dominant and late‐onset Alzheimer’s disease	13
Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort	13
National and subnational burden of stroke in Iran from 1990 to 2019	13
Deep brain stimulation effects on verbal fluency dissociated by target and active contact location	13
Long‐term adherence and response to botulinum toxin in different indications	13

Proteomics and mathematical modeling of longitudinal CSF differentiates fast versus slow ALS progression	12
Air pollution is associated with faster cognitive decline in Alzheimer's disease	12
Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants	12
Characteristics of systemic inflammation and brain iron deposition in Parkinson's disease patients	12
The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy	12
No evidence that herpes zoster is associated with increased risk of dementia diagnosis	12
“Brain age” predicts disability accumulation in multiple sclerosis	12
New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease	12
Neutrophil to lymphocyte ratio predicts early growth of traumatic intracerebral haemorrhage	12
Digital endpoints for self‐administered home‐based functional assessment in pediatric Friedreich’s ataxia	12
Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy	12
The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis	12
Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients	12
Unilateral pallidothalamic tractotomy at Forel's field H1 for cervical dystonia	12
Swallowing‐related neural oscillation: an intracranial EEG study	12
Multisystem proteinopathies (MSPs) and MSP‐like disorders: Clinical‐pathological‐molecular spectrum	12
The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion	12
Anakinra treatment for refractory cerebral autoinflammatory responses	12
A new clustering method identifies multiple sclerosis‐specific T‐cell receptors	11
Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia	11
Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent	11
Identifying miRNAs in multiple sclerosis gray matter lesions that correlate with atrophy measures	11
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology	11
Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old	11
Clinical and genetic characterization of adult‐onset leukoencephalopathy caused by CSF1R mutations	11
KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine	11
Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis	11
Newborn screening for Duchenne muscular dystrophy: A two‐year pilot study	11
Continuous and interval training attenuate encephalomyelitis by separate immunomodulatory mechanisms	11
Humoral response to neurofilaments and dipeptide repeats in ALS progression	11
Human Leukocyte Antigen Class II associations in late‐onset Myasthenia Gravis	11
Increased atrial fibrillation risk in Parkinson’s disease: A nationwide population‐based study	11
Sciatic nerve microvascular permeability in type 2 diabetes decreased in patients with neuropathy	11
Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody	11
Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease	11
LRRK2 and Parkinson's disease: from genetics to targeted therapy	11
Hold that pose: capturing cervical dystonia's head deviation severity from video	11
Evaluation of peripherin in biofluids of patients with motor neuron diseases	11
Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy	11
Long‐term continuation of anti‐seizure medications after acute stroke	11
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies	11
Mitochondrial morphology and MAVS‐IFN1 signaling pathway in muscles of anti‐MDA5 dermatomyositis	10
COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls	10
Epilepsy inMT‐ATP6‐ related mils/NARP: correlation of elettroclinical features with heteroplasmy	10
Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP	10
Combining structural and metabolic markers in a quantitative MRI study of motor neuron diseases	10
Cognitive reserve protects ALS‐typical cognitive domains: A longitudinal study.	10
Decreased neurofilament light chain levels in estriol‐treated multiple sclerosis	10
The α2δ‐1/NMDA receptor complex is involved in brain injury after intracerebral hemorrhage in mice	10
The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis	10
COVID‐19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis	10
Exosomal circ‐AHCY promotes glioblastoma cell growth via Wnt/β‐catenin signaling pathway	10
Transcriptome analysis of collagen VI‐related muscular dystrophy muscle biopsies	10
Clinical and diagnostic features of anti‐neurofascin‐155 antibody‐positive neuropathy in Han Chinese	10
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology	10
Improving quality, affordability, and equity of multiple sclerosis care	10
Responsive neurostimulation for focal motor status epilepticus	10
Loss‐of‐function variants in Kv11.1 cardiac channels as a biomarker for SUDEP	10
Using electronic health data to explore effectiveness of ICU EEG and anti‐seizure treatment	10
Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients	10
Guanabenz ameliorates disease in vanishing white matter mice in contrast to sephin1	10
Dissecting the limited genetic overlap of Parkinson's and Alzheimer's disease	10
Cyclical underreporting of seizures in patient‐based seizure documentation	10
Accelerated long‐term forgetting over three months in asymptomatic APOE ɛ4 carriers	10
A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis	10
Uridine‐responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings	10
Plasma phosphorylated tau181 predicts cognitive and functional decline	10
Vestibular syncope: clinical characteristics and mechanism	10
Effects of simvastatin on white matter integrity in healthy middle‐aged adults	10
Evidence‐based consensus guidelines for ALS genetic testing and counseling	10
Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS‐associated mtDNA mutations	10
Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis	10
Exploring diazoxide and continuous glucose monitoring as treatment for Glut1 deficiency syndrome	10
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment	10
Genetic defects are common in myopathies with tubular aggregates	10
Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype	10
Improving risk‐stratification of natalizumab‐associated PML	10
Predicting the disease severity in male individuals with ornithine transcarbamylase deficiency	10
Efficacy of melatonin in term neonatal models of perinatal hypoxia‐ischaemia	10
PINK1 antagonize intracerebral hemorrhage by promoting mitochondrial autophagy	10
Adult‐onset dominant muscular dystrophy in Greek families caused by Annexin A11	9
Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study	9
Adult‐onset rapidly worsening progressive myoclonic epilepsy caused by a novel variant in DHDDS	9
Visceral and emotional responses to direct electrical stimulations of the cortex	9
Missense PDSS1 mutations in CoenzymeQ10 synthesis cause optic atrophy and sensorineural deafness	9
MRI and fluid biomarkers reveal determinants of myelin and axonal loss with aging	9
Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia	9
Sleep disturbance and memory dysfunction in early multiple sclerosis	9
Longitudinal change in TSPO PET imaging in progressive multiple sclerosis	9
Phosphorylated alpha‐synuclein in Iba1‐positive macrophages in the skin of patients with Parkinson's disease	9
Triacetyluridine treats epileptic encephalopathy from CAD mutations: a case report and review	9
Associative cued asynchronous BCI induces cortical plasticity in stroke patients	9
Hyperventilation‐induced focal seizures in adults: think autoimmune encephalitis	9
HCMV infection and IFITM3 rs12252 are associated with Rasmussen's encephalitis disease progression	9
Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability	9